Phase I/II study to evaluate the safety and clinical efficacy of atezolizumab (atezo; aPDL1) in combination with temozolomide (TMZ) and radiation in patients with newly diagnosed glioblastoma (GBM).
Abstract No : 2511
Abstract Type : Oral Abstract Session
Indication : Glioblastoma Multiforme
Intervention : atezolizumab + temozolomide
Company : Genentech
Technology : Monoclonal antibody
Results:
60 patients were enrolled. With median follow-up time of 16.7 months (data cutoff = 30 Dec 2019), 24 patients had died and 32 had progressed. Median OS was 17.1 months (95% CI: 13.9, not reached). Median PFS was 9.7 months (95% CI: 7.6- 15). Median PFS in MGMT methylated patients (n = 18) was 16.7 months (95% CI: 7.85, not reached) and 7.9 months (95% CI: 6.70-12.4) in MGMT unmethylated patients (n = 33). Treatment-related adverse events with maximum CTCAE grade . 3 occurred in 33 patients; the most common were LFT elevation (n = 5) and lymphopenia (n = 23). To date, 17 of the enrolled 60 patients underwent re-resection post treatment with atezo. The matched paired tumor analysis of pre and post treatment tissue will provide valuable insights into mechanisms of anti-PD-L1 therapy resistance. Tumor immunocorrelative studies are pending
Conclusion:
Concurrent use of atezo with radiation and TMZ was tolerable and demonstrated modest efficacy
Commentary:
Concurrent use of atezoluzumab with radiation and TMZ was safe and demonstrated modest efficacy in line with published trials for newly diagnosed GBM.
Refer to Glioblastoma Multiforme Market report for detailed Insights.
